Back to Newsroom

hC Bioscience Inc. Establishes World Class Oncology Clinical Advisory Board; Expands Medical and Regulatory Team

Key Takeaways

  • hC Bioscience Inc. has formed an oncology clinical advisory board to guide development of its lead product for colorectal cancer liver metastasis (CRCLM)
  • The Company separately expanded its medical and regulatory team of advisors
  • The additions collectively will support the Company’s goal to bring tRNA-based therapies to patients starting with the treatment of colorectal cancer that has spread to the liver

Boston, MA, October 20, 2023 -- hC Bioscience Inc. today announced the formation of its oncology clinical advisory board to guide development of the Company’s therapeutic tRNA for the treatment of colorectal cancer that has spread to the liver (CRCLM). The advisory board is comprised of globally recognized translational and clinical researchers with extensive expertise in the areas of gastrointestinal cancer and immunotherapy. 

Separately, the Company expanded its medical and regulatory team with the appointments of three advisors, Jose Iglesias, M.D. as consulting Chief Medical Officer, Christine Swenson as Advisor, Regulatory Strategy, and Sharon Tan as acting VP, Program Management. 

“We are honored to welcome our world class clinical advisory board as well as the newest members of the medical and regulatory team," said Leslie Williams, CEO and Founder of hC Bioscience. “Together, they will contribute their global expertise in helping us advance a new class of tRNA based therapies in humans for the first time.” 

hC Bioscience is developing a family of therapeutic tRNAs called PTCX tRNA. PTCX tRNA is designed to recognize and address premature termination codons in mRNA. Premature termination codons result from gene mutations that cause cells to stop protein production too soon, resulting in truncated proteins that do not function as intended. PTCX tRNA aims to repair these mutations in a codon specific manner and restore the production of native full-length functional proteins. 

“tRNA is a promising new class of therapies for targeting colorectal cancers that have metastasized to the liver and are difficult to treat with existing technologies,” said Josep Tabernero, M.D. Ph.D., Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain and member of the Company’s oncology advisory board. “Targeting premature termination codons with their PTCX tRNA offers a potentially elegant and powerful therapeutic approach given their prevalence in the APC tumor suppressor gene in colorectal cancer.”

Colorectal cancer is the third most common malignancy worldwide and has a high mortality rate. 70% of CRC are estimated to metastasize to the liver. A major contributor to cancer growth is the loss of function in tumor suppressor genes, that would otherwise produce proteins that prevent cells from growing out of control. In colorectal cancer, the most dominant mutations are those that result in premature termination codons in the APC tumor suppressor gene. 75% of APC mutations are nonsense mutations that PTCX tRNA is designed to repair. 

The Company’s oncology clinical advisory board includes the following members: 

  • Rodrigo Dientsman, M.D. | Group Leader of VHIO´s Oncology Data Science (ODysSey) Group
  • David Goldstein, M.D. | Conjoint Clinical Professor, Senior staff specialist in the Department of Medical Oncology at Prince of Wales Hospital
  • Scott Kopetz, M.D., PhD. | Deputy Chair for Translational Research, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
  • Tim Price MBBS, FRACP DHlthSc. | Faculty of Health and Medical Sciences, University of Adelaide
  • Josep Tabernero, M.D. Ph.D. | Head of the Medical Oncology Department at the Vall d’Hebron University Hospital and former President of ESMO (2018 – 2019)
  • John Zalcberg, M.D., Ph.D. | Medical oncologist at Alfred Health and Former Head of the Cancer Research Program in the School of Public Health and Preventive Medicine at Monash University.

About hC Bioscience

hC Bioscience is dedicated to bringing tRNA-based therapies to patients. Therapeutic tRNA is a new class of treatments that target disease-causing proteins at the level of translation. 
 
Our initial focus is designing and developing therapeutic tRNAs to treat cancers driven by mutations in tumor suppressor genes, as well as inherited diseases. Our lead indications include colorectal cancer that has metastasized to the liver (CRCLM), with additional programs targeting genetic diseases. Therapeutic tRNA represents the next-generation of RNA-based therapies. It holds the potential to repair damaged proteins by modifying errors in mRNA, in a codon-specific, sequence-context-agnostic manner. This means that one single tRNA therapeutic has the potential of addressing multiple disease-causing genes.
 
hC Bioscience is based in Boston, MA, and was founded on technology out of Universities including Iowa, Wisconsin, Rochester, and Chicago. The Company secured $40 million in series A financing with investments from leading venture firms including ARCH Ventures, Takeda Ventures, 8VC, Taiho Ventures, Panacea Venture, and CureDuchene.

Key Takeaways

  • hC Bioscience Inc. has formed an oncology clinical advisory board to guide development of its lead product for colorectal cancer liver metastasis (CRCLM)
  • The Company separately expanded its medical and regulatory team of advisors
  • The additions collectively will support the Company’s goal to bring tRNA-based therapies to patients starting with the treatment of colorectal cancer that has spread to the liver
Download

Media Gallery

1) In healthy RNA, the ribosome moves seamlessly along the mRNA chain with tRNA shuttling amino acids to produce a functional, full-length protein. 2) If a mutation results in a premature termination codon, the body can be deprived of a protein essential for preventing disease. 3) Therapeutic PTCX tRNA recognizes premature termination codons, overwrites, and repairs the PTC by adding the correct amino acid and allowing for protein synthesis to continue to completion.

Quotes

“
Together, they will contribute their global expertise in helping us advance a new class of tRNA based therapies in humans for the first time.
Leslie Williams — CEO and Founder of hC Bioscience
“
Targeting premature termination codons with their PTCX tRNA offers a potentially elegant therapeutic approach given their prevalence in the APC tum...
Josep Tabernero, M.D. Ph.D., — Vall d'Hebron Institute of Oncology (VHIO)

Related Bios

Rodrigo Dientsmann, MBA, M.D.
Advisory Board Member
Dr. Dienstmann is a medical oncologist with expertise in early drug development and molecularly-guided therapies. His research is focused on integrating biomarker data with clinical outcomes to boost precision cancer therapy.Dr. Dientsmann is the Medical Director of Oncoclínicas Precision Medicine and Big Data Initiatives, in São Paulo, Brazil. As well as a researcher in the Oncology Data Science Group, at the Vall d´Hebron Institute of Oncology in Barcelona, Spain.


View Full Bio>>
David B. Goldstein, M.D.
Advisory Board Member
Prof Goldstein is a conjoint clinical professor of whom has been involved in a variety of clinical research projects ranging from laboratory basic science to novel therapeutics trials to psychosocial aspects of Cancer care. He has been PI of a number of NHMRC and Cancer Australia funded therapeutic trials including both investigator initiated and as Australian PI for multinational studies. He has also been involved with psychosocial and cross cultural/CALD research for many years. His clinical interests are treatment of GI malignancies including pancreas cancer, colorectal cancer, anal carcinoma, hepatobilary and upper GI malignancy.
View Full Bio>>
Scott Kopetz, M.D., Ph.D., FACP
Advisory Board Member
Dr. Kopetz is an Associate Professor in Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. Dr. Kopetz’ research focuses on developing an understanding of the role of protein tyrosine kinases in cancer maintenance and growth. The emphasis of the research is evaluation of targets and compounds close to application in the clinic, with an emphasis on metastatic colorectal cancer. This focus utilizes cancer cell lines as well as tissue samples from patients, including correlative samples from ongoing clinical trials of novel therapeutic agents. Currently, his lab studies the tyrosine kinase Src in tissue culture, murine colon cancer models, and patient samples, where they have established a role for Src in acquired chemotherapy resistance. Related work includes evaluation of the role of BRAF mutations in colon cancer biology, with a focus on developing rationale therapeutic combinations based on the unique biology of this subset of colorectal cancer.
View Full Bio>>
Timothy Price, M.D.
Advisory Board Member
Professor Tim Price trained in Medical oncology at the RAH and completed a Gastrointestinal Fellowship at The Royal Marsden Hospital and Institute of Cancer Research, London. He is currently Head of Clinical Oncology Research at The Queen Elizabeth Hospital, Woodville. He is also the Clinical Director of the BRAGG Comprehensive Cancer Centre of SA/NT. He has also positions as Visiting Medical Oncologist at Calvary Hospital North Adelaide, Western Hospital Henley Beach and Lyell McEwin Health Service. He is a Clinical Professor within the Faculty of Medicine, at the University of Adelaide
View Full Bio>>
Josep Tabernero, M.D., Ph.D.
Advisory Board Member
Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and he is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital, Director of the Vall d’Hebron Institute of Oncology (VHIO) and Professor of Medicine at UVic-UCC. He has been Principal Investigator of several Phase I pharmacodynamic studies and translational projects with tumor-directed targeted therapies and immune-based therapies.

His research aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation.

Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery, Clinical Cancer Research, Cancer Treatment Reviews, and Nature Reviews Clinical Oncology. He has (co) authored approximately 500 peer-reviewed papers with an H-Index of 115.

He was the President (2018 – 2019) of the European Society for Medical Oncology´s (ESMO), and also serves on its Public Policy as well as Cancer Medicines Committees. He is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO). He has also been a member of the Educational and Scientific Committees of ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, TAT and WCGIC meetings
View Full Bio>>
John Zalcberg, M.D., Ph.D.
Advisory Board Member
Professor Zalcberg's clinical areas of interests include gastrointestinal (GI) cancer, the diagnosis and management of patients with gastrointestinal tumours (GIST) and quality of care. He has published over 380 articles in peer-reviewed journals. He was the Principal Investigator for the EORTC advanced GIST trial in Australia and continues to be actively involved in trials in this disease, as well as other gastrointestinal cancers.

Professor John Zalcberg is immediate, past Head of the Cancer Research Program in the School of Public Health and Preventive Medicine at Monash University, and continues to provide academic leadership to a number of clinical quality registries. He held the inaugural Tony Charlton Chair in Cancer Research at the Alfred Hospital, Melbourne, Australia until July 2023. Prior to taking up his most recent position in 2015, he was Director of the Division of Cancer Medicine at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne for 17 years and Chief Medical Officer at that institution for 5 years.

A co-founder of the Lorne Cancer Conference and the Australasian Gastrointestinal Trials Group (AGITG), he was the prior Chair of the Board of AGITG and a previous board member of Cancer Trials Australia. He was the Co-Chair of the Cancer Drugs Alliance and immediate past Chair and current Board member of the Australian Clinical Trials Alliance. Other current Board positions include ICON, Praxis and All.Can Australia. He is also a past board member of the Cancer Institute of New South Wales, the Australian Red Cross Blood Service and past-President of the Clinical Oncological Society of Australia (COSA).

He has received several awards including a Medal of the Order of Australia (OAM), the Cancer Achievement Award from the Medical Oncology Group of Australia and the Tom Reeve Award for Outstanding Contributions to Cancer Care from COSA. In 2014, the AGITG created the annual “John Zalcberg OAM Award for Excellence in Cancer Research and in 2018 he was awarded the Red Cross Distinguished Service Medal. Most recently (June 2023), he was awarded an AO (Officer in the General Division of the Order of Australia).
View Full Bio>>
Jose Iglesias, M.D.
Chief Medical Officer, Consultant
Dr. Iglesias has more than 30 years of experience in oncology. This includes his work at Boston Biomedical Inc., where he was responsible for the clinical development of seven early pipeline compounds in immuno-oncology, solid tumor oncology and hematologic malignancies.

Previously, José was CMO at Biothera and Bionomics, where he was responsible for the clinical development of their oncology pipelines, including Imprime-PGG, antivascular agents, monoclonal antibodies and small molecule kinase inhibitors. Before that, he was CMO at Abraxis Bioscience and served as vice president, clinical development, at Celgene Corporation, where he was responsible for the Phase III development of Abraxane in pancreatic cancer, lung cancer and metastatic breast cancer. Before Abraxis/Celgene, Jose spent 10 years with Eli Lilly in Canada, the US and Australia, where he was oncology medical advisor for the Asia-Pacific Region.

José is author or co-author of more than 60 publications in the area of Oncology, with over 9,000 citations. He received his M.D. from the Universidad de Montevideo, Uruguay and completed an oncology post-doctoral fellowship at the University of Toronto.
View Full Bio>>
Christine Swenson
Advisor, Regulatory Strategy
Christine Swenson is a global regulatory affairs executive with more than 35 years of drug development experience. She has a proven record of developing and overseeing innovative regulatory strategies spanning all stages of clinical development across multiple therapeutic areas for drugs, biologics, mRNA vaccines & therapeutics as well as cell, gene, and gene editing therapies, leading successful regulatory submissions and health authority interactions. Ms Swenson was formerly the senior vice president of regulatory affairs at Beam Therapeutics, establishing the foundation to advance base editing to clinical trials. As the SVP, global regulatory affairs at Moderna, she led the development and execution of regulatory strategies for its portfolio of mRNA therapeutics and vaccines. Prior to Moderna, she held leadership roles in regulatory affairs and quality at Bristol-Myers Squibb, Adnexus, ImmunoGen and Coley Pharmaceutical Group.

Ms Swenson received a BS in biology from Stonehill College.
View Full Bio>>
Sharon Tan
VP, Program Management, Consultant
As the Founder and Owner of Tangram Development Solutions, Ms. Tan is a results-driven executive with over two decades of expertise in medical device and drug product development, encompassing the entire product lifecycle from concept to commercialization. Proficient in navigating global drug development, regulatory interactions, and requirements, including specialized pathways like Breakthrough Designation, PRIME, and Sakigake for rare diseases and immuno-oncology. Ms. Tan has a strong track record in building and leading high-performing cross-functional teams within a dynamic and collaborative environment, fostering a culture of teamwork and unity, while also mentoring and developing team members to attain organizational objectives.
View Full Bio>>
Leslie Williams
Co-Founder, President & CEO
Leslie J Williams, a 25-year biopharmaceutical industry veteran, is an experienced biotech CEO and board of directors’ member with demonstrated expertise in building companies, raising funds, and negotiating strategic collaborations.

Leslie is founding CEO, President & Director of hC Bioscience, Inc. an innovator and leader in protein editing with tRNA based therapeutics. She also serves on the Board of Directors for Ocular Therapeutix (OCUL), Windtree Therapeutics (WINT), and CSCRI (Coral Sea Clinical Research Institute). In addition, she serves on the Editorial Advisory Board of Life Science Leader, the Advisory Board of Life Science Cares and serves as an EIR at UVA and University of Iowa. Ms. Williams was formerly the founder and CEO of ImmusanT, developing immunotherapies for autoimmune diseases and was CEO at Ventaira Pharmaceuticals developing therapies using the lung as a portal for delivery. Williams prior pharmaceutical experience includes INO Therapeutics, Merck and GSK. She was also a venture partner at Battelle Ventures where she sourced and evaluated deals and assisted early-stage technology companies with strategy, management, business development and M&A.

Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree with honors in nursing from the University of Iowa. Before entering the industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa.
View Full Bio>>

Contacts

Savannah Beaver
savannah@reportablenews.com
(617) 804-0366
Media